Next Article in Journal
The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
Previous Article in Journal
Tumor Biological Feature and Its Association with Positive Surgical Margins and Apical Margins after Radical Prostatectomy in Non-Metastasis Prostate Cancer
Open AccessCase Report

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib

1
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
2
Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA
3
Department of Neuro Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
4
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
5
Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(2), 1537-1543; https://doi.org/10.3390/curroncol28020145
Received: 24 March 2021 / Revised: 12 April 2021 / Accepted: 15 April 2021 / Published: 18 April 2021
Recurrent meningiomas remain a substantial treatment challenge given the lack of effective therapeutic options aside from surgery and radiation therapy, which yield limited results in the retreatment situation. Systemic therapies have little effect, and responses are rare; the search for effective systemic therapeutics remains elusive. In this case report, we provide data regarding significant responses in two radiographically diagnosed intracranial meningiomas in a patient with concurrent thyroid carcinoma treated with cabozantinib, an oral multitarget tyrosine kinase inhibitor with potent activity against MET and VEGF receptor 2. Given the clinical experience supporting the role of VEGF agents as experimental therapeutics in meningioma and the current understanding of the biological pathways underlying meningioma growth, this may represent a new oral therapeutic alternative, warranting prospective evaluation. View Full-Text
Keywords: meningioma; cabozantinib; VEGF; targeted therapy meningioma; cabozantinib; VEGF; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Kotecha, R.; Tonse, R.; Appel, H.; Odia, Y.; Kotecha, R.R.; Rabinowits, G.; Mehta, M.P. Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. Curr. Oncol. 2021, 28, 1537-1543. https://doi.org/10.3390/curroncol28020145

AMA Style

Kotecha R, Tonse R, Appel H, Odia Y, Kotecha RR, Rabinowits G, Mehta MP. Regression of Intracranial Meningiomas Following Treatment with Cabozantinib. Current Oncology. 2021; 28(2):1537-1543. https://doi.org/10.3390/curroncol28020145

Chicago/Turabian Style

Kotecha, Rupesh; Tonse, Raees; Appel, Haley; Odia, Yazmin; Kotecha, Ritesh R.; Rabinowits, Guilherme; Mehta, Minesh P. 2021. "Regression of Intracranial Meningiomas Following Treatment with Cabozantinib" Curr. Oncol. 28, no. 2: 1537-1543. https://doi.org/10.3390/curroncol28020145

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop